{"url_path":"/sec/adct/8-k/2026-07-02/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1771910/0000950103-26-010195-index.html","accession_number":"0000950103-26-010195","cik":"0001771910","ticker":"ADCT","issuer_name":"ADC Therapeutics SA","edgar_url":"https://www.sec.gov/Archives/edgar/data/1771910/0000950103-26-010195-index.html","primary_entity_key":"0001771910","primary_entity_name":"ADC Therapeutics SA"},"word_count":324,"has_tables":true,"body_markdown":"**Item 5.02. Departure of Directors or Certain Officers; Election\nof Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**\n\n \n\nOn June 30, 2026, the Board of Directors of ADC Therapeutics SA (the\n“Company”), with the advice of its independent compensation consultant, approved one-time retention awards (“Awards”)\nto certain of the Company’s employees, including its named executive officers as set forth below:\n\n \n\nName\nTitle\nCash Incentive Award\nRSU Award\n\nAmeet Mallik\nChief Executive Officer\n$1,795,500\n675,000\n\nJose Carmona\nChief Financial Officer\n$541,842\n203,700\n\nMohamed Zaki\nChief Medical Officer\n$568,974\n213,900\n\n \n\nThe Awards were granted pursuant to incentive award letter agreements\n(the “Incentive Award Agreements”) that set forth the terms and conditions of the respective Awards.\n\n \n\nThe cash portion will be paid on or about July 15, 2026. The cash portion\nis subject to repayment if the named executive officer’s employment with the Company terminates before June 30, 2027. Such repayment\nobligation will not apply if employment is terminated by the Company without cause or by the named executive officer for good reason.\n\n \n\nThe RSU portion was granted on June 30, 2026. The RSUs will vest upon\nthe earlier of (x) June 30, 2027 and (y) termination of employment by the Company without cause or by the named executive officer for\ngood reason, subject to the named executive officer’s continued employment with the Company on the vesting date.\n\n \n\nThe foregoing description of the Incentive Award Agreements does not\npurport to be complete and is qualified in its entirety by reference to the Incentive Award Agreements, which will be filed with the Company’s\nQuarterly Report on Form 10-Q for the quarter ended June 30, 2026.\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934,\nthe registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n**ADC Therapeutics SA**\n\n \n \n\nDate: July 2, 2026\n \n\n \nBy:\n/s/ Peter J. Graham\n\n \nName:\nPeter J. Graham\n\n \nTitle:\nChief Legal Officer"}